Literature DB >> 23180119

Chest-tube drainage is a sign of acute exacerbation of interstitial lung disease associated with lung cancer.

Tomohiro Maniwa1, Mitsuhiro Isaka, Kazuo Nakagawa, Yasuhisa Ohde, Takehiro Okumura, Masahiro Endo, Haruhiko Kondo.   

Abstract

PURPOSE: Interstitial lung disease (ILD) is associated with primary lung cancer and an increased risk of postoperative acute exacerbation (AE). Although the preoperative factors associated with AE of ILD are well described, there is little information about the postoperative factors. Thus, the present study focuses on the postoperative management of chest-tube drainage associated with AE of ILD.
METHODS: We conducted a retrospective chart study of 1,309 patients with lung cancer, who underwent pulmonary resection at Shizuoka Cancer Center between September 2002 and January 2011. ILD was diagnosed by chest computed tomography (CT) findings in 95 patients. After the exclusion of 6 patients with a history of pneumonectomy, the subjects of this study were 8 patients who suffered AE after surgery (AE group) and 81 patients (non-AE group) who did not. We investigated the clinicopathological findings and postoperative management of chest-tube drainage in the two groups.
RESULTS: The clinicopathological findings of the two groups did not differ significantly. The chest tubes could not be removed before postoperative day 5 because of pleural effusion in 5 patients (62.5 %) from the AE group and 12 patients (14.8 %) from the non-AE group (P = 0.0040).
CONCLUSIONS: The postoperative volume draining from the chest-tube is an important sign of AE of ILD.

Entities:  

Mesh:

Year:  2012        PMID: 23180119     DOI: 10.1007/s00595-012-0428-x

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  20 in total

Review 1.  Acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Robert Hyzy; Steven Huang; Jeffrey Myers; Kevin Flaherty; Fernando Martinez
Journal:  Chest       Date:  2007-11       Impact factor: 9.410

2.  Acute interstitial pneumonia following surgery for primary lung cancer.

Authors:  Masashi Muraoka; Tsutomu Tagawa; Shinji Akamine; Tadayuki Oka; Tomoshi Tsuchiya; Masato Araki; Tomayoshi Hayashi; Takeshi Nagayasu
Journal:  Eur J Cardiothorac Surg       Date:  2006-08-08       Impact factor: 4.191

3.  Prediction of acute pulmonary complications after resection of lung cancer in patients with preexisting interstitial lung disease.

Authors:  J S Park; H K Kim; K Kim; J Kim; Y M Shim; Y S Choi
Journal:  Thorac Cardiovasc Surg       Date:  2011-04-08       Impact factor: 1.827

4.  Effect of prolonged low-dose methylprednisolone therapy in acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  O Nishiyama; M Shimizu; Y Ito; H Kume; R Suzuki; T Yokoi; K Yamaki
Journal:  Respir Care       Date:  2001-07       Impact factor: 2.258

5.  The disappearance of subpleural and interlobular lymphatics in idiopathic pulmonary fibrosis.

Authors:  Masahito Ebina; Naoko Shibata; Hiromitsu Ohta; Shu Hisata; Tsutomu Tamada; Masao Ono; Kenta Okaya; Takashi Kondo; Toshihiro Nukiwa
Journal:  Lymphat Res Biol       Date:  2010-12       Impact factor: 2.589

6.  Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure.

Authors:  J B Stern; H Mal; O Groussard; O Brugière; A Marceau; G Jebrak; M Fournier
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

7.  Low-dose steroid therapy at an early phase of postoperative acute respiratory distress syndrome.

Authors:  Hyun-Sung Lee; Jong Mog Lee; Moon Soo Kim; Hyae Young Kim; Bin Hwangbo; Jae Ill Zo
Journal:  Ann Thorac Surg       Date:  2005-02       Impact factor: 4.330

8.  Predictive factors for postoperative acute exacerbation of interstitial pneumonia combined with lung cancer.

Authors:  Yasushi Shintani; Mitsunori Ohta; Teruo Iwasaki; Naoki Ikeda; Emiko Tomita; Kunimitsu Kawahara; Yuko Ohno
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-04-18

Review 9.  Clinical advances in the diagnosis and therapy of the interstitial lung diseases.

Authors:  Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2005-05-05       Impact factor: 21.405

10.  Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes.

Authors:  Masako Chiyo; Yasuo Sekine; Takekazu Iwata; Koichiro Tatsumi; Kazuhiro Yasufuku; Akira Iyoda; Mizuto Otsuji; Shigetoshi Yoshida; Kiyoshi Shibuya; Toshihiko Iizasa; Yukio Saitoh; Takehiko Fujisawa
Journal:  J Thorac Cardiovasc Surg       Date:  2003-10       Impact factor: 5.209

View more
  5 in total

Review 1.  Lung cancer and interstitial lung disease: a literature review.

Authors:  Jean-Marc Naccache; Quentin Gibiot; Isabelle Monnet; Martine Antoine; Marie Wislez; Christos Chouaid; Jacques Cadranel
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

2.  Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis.

Authors:  Takekazu Iwata; Shigetoshi Yoshida; Kaoru Nagato; Takahiro Nakajima; Hidemi Suzuki; Tetsuzo Tagawa; Teruaki Mizobuchi; Satoshi Ota; Yukio Nakatani; Ichiro Yoshino
Journal:  Surg Today       Date:  2014-11-22       Impact factor: 2.549

3.  Effect of collagen vascular disease-associated interstitial lung disease on the outcomes of lung cancer surgery.

Authors:  Hideyuki Maeda; Masato Kanzaki; Kei Sakamoto; Tamami Isaka; Kunihiro Oyama; Masahide Murasugi; Takamasa Onuki
Journal:  Surg Today       Date:  2017-02-28       Impact factor: 2.549

4.  Risk factors for acute exacerbation of interstitial lung disease following lung cancer resection: a systematic review and meta-analysis.

Authors:  Xiaohu Hao; Jianqi Hao; Cong Chen; Haoning Peng; Jian Zhang; Qi Cao; Lunxu Liu
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-05-02

5.  Impact of interstitial lung disease on postoperative morbidity and 90-day mortality after pulmonary resection.

Authors:  Weipeng Shao; Jingjing Huang; Hongxiang Feng; Hongliang Sun; Yanhong Ren; Xiaowei Wang; Zhenrong Zhang; Deruo Liu
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.